BRIDGE: An open-label phase II trial evaluating the safety of bevacizumab + carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 6, Issue 1, 2011, Pages 109-114

  Hainsworth, John D ^a   Fang, Liang ^b   Huang, Jane E ^b   Karlin, David ^b   Russell, Kenneth ^c   Faoro, Leonardo ^b   Azzoli, Christopher ^d  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b GENENTECH INC   (United States)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Bevacizumab; Delayed initiation; Non small cell lung cancer; Pulmonary hemorrhage; Squamous

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; HEPARIN; PACLITAXEL; WARFARIN;

ADULT; AGED; ARTICLE; ASTHENIA; BASAL GANGLIA INFARCTION; BRAIN ISCHEMIA; CANCER GROWTH; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONGESTIVE HEART FAILURE; DEEP VEIN THROMBOSIS; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HEMOPTYSIS; HIP FRACTURE; HUMAN; HYPERTENSION; HYPERTENSION ENCEPHALOPATHY; INFARCTION; INFECTION; LEUKOENCEPHALOPATHY; LOW DRUG DOSE; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MALE; MORBIDITY; MULTIPLE CYCLE TREATMENT; PAIN; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; SMALL INTESTINE OBSTRUCTION; SQUAMOUS CELL CARCINOMA; THORAX PAIN;

EID: 78651060614     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181f94ad4     Document Type: Article

References (23)

1. American Cancer Society. Cancer Facts & Figures 2009. Atlanta: American Cancer Society, 2009.
2. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-2191.
3. Novotny WF, Holmgren E, Griffing S, et al. Identification of squamous cell histology and central, cavitary tumors as possible risk factors for pulmonary hemorrhage in patients with advanced NSCLC receiving bevacizumab. Proc Am Soc Clin Oncol 2001:abstract 1318.
4. Sandler AB, Schiller JH, Gray R, et al. Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab. J Clin Oncol 2009;27:1405-1412.
5. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 2006;355: 2542-2550.
6. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 2009; 27:1227-1234.
7. Data-on-file. Basel, Switzerland: Hoffmann-LaRoche Ltd., 2009.
8. Data-on-file. South San Francisco, CA: Genentech Inc., 2009.
9. Paesmans M, Sculier JP, Libert P, et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. J Clin Oncol 1995;13:1221-1230.
10. Hoang T, Xu R, Schiller JH, et al. Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on Eastern Cooperative Oncology Group data. J Clin Oncol 2005;23:175-183.
11. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol , 2008, 26, 3543-3551.
12. Giovannetti E, Mey V, Nannizzi S, et al. Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 2005;68:110-118.
13. Peterson P, Park K, Fossella F, et al. Is pemetrexed more effective in patients with non-squamous histology? A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC) [abstract 6521]. European Cancer Conference, Barcelona, Spain, September 23, 2007.
14. Sequist LV, Martins RG, Spigel D, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008;26:2442-2449.
15. Rodenhuis S, van de Wetering ML, Mooi WJ, et al. Mutational activation of the K-ras oncogene: a possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med 1987;317:929-935.
16. Karp DD, Novello S, Cardenal F, et al. Continued high activity of figitumumab (CP-751,871) combination therapy in squamous lung cancer. J Clin Oncol 2009;27(15s):abstract 8072.
17. Tolcher AW, Sarantopoulos J, Patnaik A, et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 2009;27:5800-5807.
18. Hidalgo M, Tirado Gomez M, Lewis N, et al. A phase I study of MK-0646, a humanized monoclonal antibody against the insulin-like growth factor receptor type 1 (IGF1R) in advanced solid tumor patients in a q2 wk schedule. J Clin Oncol 2008;26(Suppl):Abstract 3520.
19. Martin LP, Kozloff MF, Krzakowski M, et al. Axitinib (AG-013736; AG) combined with chemotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) and other solid tumors. J Clin Oncol 2009;27(15s):Abstract 3559.
20. Cohen EW, Davis DW, Karrison TG, et al. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol 2009;10:247-257.
21. Seiwert TY, Haraf DJ, Cohen EE, et al. A phase I study of bevacizumab (B) with fluorouracil (F) and hydroxyurea (H) with concomitant radiotherapy (X) (B-FHX) for poor prognosis head and neck cancer (HNC) [abstract]. J Clin Oncol 2006;24(Suppl 18):5530.
22. Choong NW, Haraf DJ, Cohen EE, et al. Randomized phase II study of concomitant chemoradiotherapy with 5-fluorouracil-hydroxyurea (FHX) compared to FHX and bevazicumab (BFHX) in intermediate stage head and neck cancer (HNC) [abstract]. J Clin Oncol 2007;25(Suppl 18): 6034.
23. Enzinger PC, Fidias P, Meyerhardt J, et al. Phase II study of bevacizumab and docetaxel in metastatic esophageal and gastric cancer. ASCO Gastrointestinal Cancers Symposium, 2006: Abstract 68.